These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28708433)

  • 21. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
    Simeone JC; Marcoux RM; Quilliam BJ
    J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of newer antipsychotics on extrapyramidal function.
    Tarsy D; Baldessarini RJ; Tarazi FI
    CNS Drugs; 2002; 16(1):23-45. PubMed ID: 11772117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions.
    Sekine Y; Rikihisa T; Ogata H; Echizen H; Arakawa Y
    Eur J Clin Pharmacol; 1999 Oct; 55(8):583-7. PubMed ID: 10541776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changing trends in pediatric antipsychotic use in Florida's Medicaid program.
    Constantine R; Tandon R
    Psychiatr Serv; 2008 Oct; 59(10):1162-8. PubMed ID: 18832502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spillover effects of state medicaid antipsychotic prior authorization policies in US commercially insured youth.
    Spence O; Reeves G; dosReis S
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1064-1071. PubMed ID: 32558177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prevalence of akathisia in patients receiving stable doses of clozapine.
    Chengappa KN; Shelton MD; Baker RW; Schooler NR; Baird J; Delaney J
    J Clin Psychiatry; 1994 Apr; 55(4):142-5. PubMed ID: 7915271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disorders.
    Ayyagari R; Thomason D; Mu F; Philbin M; Carroll B
    J Med Econ; 2020 Feb; 23(2):204-212. PubMed ID: 31663802
    [No Abstract]   [Full Text] [Related]  

  • 28. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managing antipsychotic-induced tardive dyskinesia.
    Gardos G
    Drug Saf; 1999 Feb; 20(2):187-93. PubMed ID: 10082074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low Dose Loxapine: Neuromotor Side Effects and Tolerability in Autism Spectrum Disorders.
    Hellings JA; Jadhav M; Jain S; Jadhav S; Genovese A
    J Child Adolesc Psychopharmacol; 2015 Oct; 25(8):618-24. PubMed ID: 26485086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High Incidence and Prevalence of Drug-Related Movement Disorders in Young Patients With Psychotic Disorders.
    Mentzel TQ; Lieverse R; Bloemen O; Viechtbauer W; van Harten PN;
    J Clin Psychopharmacol; 2017 Apr; 37(2):231-238. PubMed ID: 28141621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of prior authorization policies on medicaid-enrolled children's use of antipsychotic medications: evidence from two mid-Atlantic states.
    Stein BD; Leckman-Westin E; Okeke E; Scharf DM; Sorbero M; Chen Q; Chor KH; Finnerty M; Wisdom JP
    J Child Adolesc Psychopharmacol; 2014 Sep; 24(7):374-81. PubMed ID: 25144909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Motor and mental side effects of clozapine.
    Gerlach J; Peacock L
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():107-9. PubMed ID: 7961551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cocaine is a major risk factor for antipsychotic induced akathisia, parkinsonism and dyskinesia.
    Maat A; Fouwels A; de Haan L
    Psychopharmacol Bull; 2008; 41(3):5-10. PubMed ID: 18779773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
    Tarsy D; Baldessarini RJ
    Mov Disord; 2006 May; 21(5):589-98. PubMed ID: 16532448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.
    Modestin J; Wehrli MV; Stephan PL; Agarwalla P
    Schizophr Res; 2008 Mar; 100(1-3):97-107. PubMed ID: 18055180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and pattern of antipsychotic induced movement disorders in a tertiary care teaching hospital in India - a cross-sectional study.
    Desai N; Patel PB; Shah S; Patel TK; Shah SN; Vatsala E
    Int J Psychiatry Clin Pract; 2018 Jun; 22(2):101-108. PubMed ID: 28952832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tardive dyskinesia in older patients.
    Jeste DV
    J Clin Psychiatry; 2000; 61 Suppl 4():27-32. PubMed ID: 10739328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurological complications of psychiatric drugs: clinical features and management.
    Haddad PM; Dursun SM
    Hum Psychopharmacol; 2008 Jan; 23 Suppl 1():15-26. PubMed ID: 18098217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.